The most common off-target bypass signalling, detected in sotorasib and adagrasib resistant tumours, includes MET amplification, BRAF, NRAS, MAP2K1 mutations and RET, ALK, BRAF, FGFR and RAF1 fusions [120]. This evidence concerns the gene ALK and neoplasm.